

Amendments to the Claims:

1. (Currently amended) An isolated nucleic acid molecule having a nucleotide sequence selected from the group consisting of:
 - a) the nucleotide sequence set forth in SEQ ID NO:1;
 - b) a nucleotide sequence encoding the amino acid sequence set forth in SEQ ID NO:2;
 - c) a nucleotide sequence having at least about 90 % sequence identity across the full length of the to the nucleotide sequence set forth in SEQ ID NO:1, wherein said nucleotide sequence having at least about 90% sequence identity to the nucleotide sequence set forth in SEQ ID NO:1 encodes a polypeptide having *Bacillus thuringiensis* (Bt) toxin binding activity;
 - d) a nucleotide sequence having at least about 95 % sequence identity across the full length of the to the nucleotide sequence set forth in SEQ ID NO:1, wherein said nucleotide sequence having at least about 95% sequence identity to the nucleotide sequence set forth in SEQ ID NO:1 encodes a polypeptide having *Bt* toxin binding activity;
 - e) ~~a nucleotide sequence that hybridizes to the complement of the nucleotide sequence set forth in SEQ ID NO:1 under stringent conditions, wherein said nucleotide sequence that hybridizes to the complement of the nucleotide sequence set forth in SEQ ID NO:1 under stringent conditions encodes a polypeptide having *Bt* toxin binding activity;~~
 - f) the nucleotide sequence of the cDNA insert of the plasmid deposited with the ATCC as Patent Deposit No. PTA-4935; and
 - gf) a nucleotide sequence complementary across the full length of to at least one nucleotide sequence set forth in a), b), c), d), or e), and f).

2. (Original) The nucleic acid molecule of claim 1, wherein said nucleic acid molecule comprises a nucleotide sequence encoding a polypeptide having Cry1A toxin binding activity.

3. (Original) The nucleic acid molecule of claim 2, wherein said nucleic acid molecule comprises a nucleotide sequence encoding a polypeptide having Cry1A(b) toxin binding activity.

4-8. (Canceled)

9. (Original) An expression cassette comprising at least one nucleotide sequence according to claim 1, wherein said nucleotide sequence is operably linked to a promoter that drives expression in a cell of interest.

10. (Original) The expression cassette of claim 9, wherein said cell of interest is selected from the group consisting of insect cells and mammalian cells.

11. (Original) The expression cassette of claim 9, wherein said cell of interest is a microorganism.

12. (Original) The expression cassette of claim 11 wherein said microorganism is selected from the group consisting of yeast and bacteria.

13. (Currently amended) A transformed cell of interest having stably incorporated within its genome a nucleotide sequence selected from the group consisting of:

- a) the nucleotide sequence set forth in SEQ ID NO:1;
- b) a nucleotide sequence encoding the amino acid sequence set forth in SEQ ID NO:2;
- c) a nucleotide sequence having at least about 90 % sequence identity across the full length of the ~~to the~~ nucleotide sequence set forth in SEQ ID NO:1, wherein said nucleotide sequence having at least about 90% sequence identity to the nucleotide sequence set forth in SEQ ID NO:1 encodes a polypeptide having *Bt* toxin binding activity;

- d) a nucleotide sequence having at least about 95 % sequence identity across the full length of the to the nucleotide sequence set forth in SEQ ID NO:1, wherein said nucleotide sequence having at least about 95% sequence identity to the nucleotide sequence set forth in SEQ ID NO:1 encodes a polypeptide having *Bt* toxin binding activity;
- e) ~~a nucleotide sequence that hybridizes to the complement of the nucleotide sequence set forth in SEQ ID NO:1 under stringent conditions, wherein said nucleotide sequence that hybridizes to the complement of the nucleotide sequence set forth in SEQ ID NO:1 under stringent conditions encodes a polypeptide having *Bt* toxin binding activity;~~
- f) the nucleotide sequence of the cDNA insert of the plasmid deposited with the ATCC as Patent Deposit No PTA-4935; and
- g) a nucleotide sequence complementary across the full length of to at least one nucleotide sequence set forth in a), b), c), d), or e), f), or g).

14. (Original) The transformed cell of claim 13, wherein said cell is a plant cell.

15. (Original) The transformed cell of claim 14, wherein said plant cell is monocotyledonous.

16-20. (Canceled)